Develops therapies for virus-associated cancers, focusing on Epstein-Barr virus (EBV)-positive malignancies.
Viracta Therapeutics, Inc., based in Cardiff-by-the-Sea, California, operates as a leading precision oncology firm focused on advancing treatments for virus-associated malignancies. Central to its innovative approach is Nana-val, a compelling candidate that combines nanatinostat and valganciclovir, currently undergoing Phase II clinical trials for Epstein-Barr virus-positive (EBV+) lymphoma. The company also spearheads an open-label Phase 2 basket trial aimed at treating a spectrum of relapsed/refractory EBV+ lymphomas, alongside a Phase 1b/2 trial targeting EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Viracta Therapeutics' diverse pipeline includes vecabrutinib, a promising non-covalent inhibitor of ITK/BTK in clinical stages of development. Additionally, VRx-510 (formerly SNS-510), a preclinical PDK-1 inhibitor, holds potential across various oncological indications. The company remains committed to exploring strategic collaborations and expanding development opportunities for vecabrutinib in conjunction with chimeric antigen receptor T-cell therapies, while advancing VRx-510 towards clinical evaluation.
Originally established as Sunesis Pharmaceuticals, Inc., Viracta Therapeutics underwent a transformative rebranding in February 2021. Since its inception in 1998, the company has been dedicated to pushing the boundaries of oncological research, leveraging its deep expertise in precision medicine to pioneer groundbreaking therapies that target viral-associated cancers, thereby enhancing treatment outcomes for patients globally.